Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-04-18 Board/Management Inform…
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: CBTT tờ trình danh sách ứng cử Thành viên HĐQT nhiệm kỳ 2023-2027
Board/Management Information Classification · 85% confidence The document is a formal periodic disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange outlining the Board of Directors’ proposal (tờ trình) for the number of directors and the list of nominees for the 2023–2027 term to be approved at the upcoming Annual General Meeting. It contains detailed biographies of proposed board members and is submitted as a management/board announcement rather than financial results, proxy forms, or an investor slide deck. It therefore best fits the Board/Management Information category.
2023-04-18 Vietnamese
IMP: Giải trình biến động KQKD quý 1/2023 so với cùng kỳ năm trước
Regulatory Filings Classification · 84% confidence The document is a compliance letter filed with the State Securities Commission and stock exchange, providing an explanation for more than 10% quarterly fluctuations in Q1 2023 vs Q1 2022 sales and profits. It is not a full interim report or earnings release, but a regulatory submission explaining variances. Under the taxonomy, this falls under general regulatory filings (RNS).
2023-04-17 Vietnamese
IMP: Nghị quyết nội dung cuộc họp HĐQT ngày 14/04/2023
Board/Management Information Classification · 85% confidence The document is an official disclosure to the Vietnamese State Securities Commission and Ho Chi Minh Stock Exchange containing the Board of Directors’ Resolution No. 04/2023/NQ-HĐQT-IMP. It describes board decisions including approval of Q1 2023 business results, Q2 2023 plan, nomination of a director candidate, and use of bad debt provisions. This is not a full financial report, earnings release, or proxy statement but an announcement of board-level resolutions and management/board-related decisions. Therefore, it best fits the Board/Management Information category (MANG).
2023-04-14 Vietnamese
IMP: Link công bố báo cáo thường niên năm 2022
Report Publication Announcement Classification · 85% confidence The document is a brief announcement filed by Imexpharm on the SEC and stock exchange portals stating that its Annual Report for fiscal year 2022 is available at a provided URL. It does not contain the report’s financial data itself but merely discloses its publication and provides a link. This matches the definition of a Report Publication Announcement (RPA).
2023-04-11 Vietnamese
IMP: Làm rõ phạm vi thu hồi giấy chứng nhận đủ điều kiện kinh doanh dược trong lĩnh vực XNK
Regulatory Filings Classification · 90% confidence The document is a joint company and Ministry of Health administrative decision concerning the voluntary revocation of a pharmaceutical business certificate and the formal government decision and certificate annex. It contains no financial results, investor materials, share issuance, management changes, or legal proceedings. It is a regulatory/compliance announcement falling outside the other specialized categories, so it best fits the fallback “Regulatory Filings” (RNS).
2023-04-11 Vietnamese
IMP: Giấy chứng nhận đăng ký doanh nghiệp thay đổi lần thứ 30
Regulatory Filings Classification · 88% confidence The document is a compliance disclosure filed on the State Securities Commission and Ho Chi Minh Stock Exchange portals, providing the updated 30th Business Registration Certificate and details of the legal representative’s citizen ID update. It is not a financial report, earnings release, management appointment notice, or dividend declaration, but rather a general regulatory announcement of a corporate registration change. Therefore it falls under the fallback category Regulatory Filings (RNS).
2023-04-11 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.